Bisphosphonates may reduce risk of certain breast, colon, and lung cancers
the ONA take:
According to two new studies published in the journal Proceedings of the National Academy of Sciences (PNAS), researchers at the Icahn School of Medicine at Mount Sinai in New York, New York, have found that bisposphonates, a commonly used class of drug to treat osteoporosis, may also prevent certain types of breast, colon, and lung cancers.
The first study analyzes how bisphosphonates block abnormal tumor growth through the human epidermal growth factor (HER) receptors, and the second study describes how bisphosphonates could be used in cancer prevention, in combination with existing treatments, and against treatment-resistant cancers. Certain types of breast, colon, and non-small cell lung cancers are driven by genetic mutations that cause the overexpression of HER family receptors.
The study found that bisphosphonates bind to kinase domains for HER proteins, thereby preventing pathway signaling that would ultimately cause cancer growth. This mechanism is similar to that of drugs that inhibit tyrosine kinases like trastuzumab and erlotinib; however, cancers often become resistant to these treatments after the tumor develops a second genetic mutation.
The findings suggest that bisphosphonates may continue to inhibit HER family receptors even after a second mutation is present, making these drugs a potential treatment for those cancers that become resistant to primary therapy.
Bisposphonates may also prevent certain types of breast, colon, and lung cancers.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|